Non-Myelofibrosis Chronic Myeloproliferative Neoplasm Patients Show Better Seroconversion Rates after SARS-CoV-2 Vaccination Compared to Other Hematologic Diseases: A Multicentric Prospective Study of KroHem.

Content Provider	Europe PMC
Author	Sertić, Zrinka Lucijanić, Marko Bašić-Kinda, Sandra Serventi Seiwerth, Ranka Periša, Vlatka Sertić, Dubravka Coha, Božena Pulanić, Dražen Perić, Zinaida Desnica, Lana Mikulić, Mirta Vodanović, Marijo Radman-Livaja, Ivo Šegulja, Dragana Rogić, Dunja Valković, Toni Aurer, Igor Duraković, Nadira
Editor	Rutella, Sergio
Copyright Year	2022
Abstract	Disease- and treatment-mediated immunodeficiency might render SARS-CoV-2 vaccines less effective in patients with hematologic diseases. We performed a prospective non-interventional study to evaluate humoral response after one and two doses of mRNA-1273, BNT162b2, or ChAdOx1 nCoV-19 vaccine in 118 patients with different malignant or non-malignant hematologic diseases from three Croatian treatment centers. An electrochemiluminescent assay was used to measure total anti-SARS-CoV-2 S-RBD antibody titers. After one vaccine dose, 20/66 (33%) achieved seropositivity with a median antibody titer of 6.1 U/mL. The response rate (58/90, 64.4%) and median antibody titer (>250 U/mL) were higher after two doses. Seropositivity varied with diagnosis (overall p < 0.001), with the lowest rates in lymphoma (34.6%) and chronic lymphocytic leukemia (52.5%). The overall response rate in chronic myeloproliferative neoplasms (CMPN) was 81.3% but reached 100% in chronic myeloid leukemia and other non-myelofibrosis CMPN. At univariable analysis, age > 67 years, non-Hodgkin’s lymphoma, active treatment, and anti-CD20 monoclonal antibody therapy increased the likelihood of no vaccine response, while hematopoietic stem cell recipients were more likely to respond. Age and anti-CD20 monoclonal antibody therapy remained associated with no response in a multivariable model. Patients with the hematologic disease have attenuated responses to SARS-CoV-2 vaccines, and significant variations in different disease subgroups warrant an individualized approach.
Journal	Biomedicines
Volume Number	10
PubMed Central reference number	PMC9687514
Issue Number	11
PubMed reference number	36428459
e-ISSN	22279059
DOI	10.3390/biomedicines10112892
Language	English
Publisher	MDPI
Publisher Date	2022-11-11
Access Restriction	Open
Rights License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). © 2022 by the authors.
Subject Keyword	SARS-CoV-2 vaccination COVID-19 chronic myeloproliferative neoplasms chronic myeloid leukemia non-Hodgkin’s lymphoma chronic lymphocytic leukemia humoral immune response anti-CD20 monoclonal antibody
Content Type	Text
Resource Type	Article
Subject	Medicine Biochemistry, Genetics and Molecular Biology